Physician profile
Jerry G Newman
NPI 1962401760
$7,358.78
in general payments reported to CMS, 2019-2025
20 companies · $704 in 2025
The $704 reported for 2025 was more than what 82% of Forensic Psychiatry providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $674 · 2020: $1,014 · 2021: $979 · 2022: $2,308 · 2023: $805 · 2024: $875 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,336 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,335.92 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,583.45 | 2020-2024 | Neurostar Tms Therapy System |
| Teva Pharmaceuticals USA, INC. | $876.24 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $762.87 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $728.22 | 2019-2024 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $602.54 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $492.61 | 2019-2023 | Trintellix |
| Vanda Pharmaceuticals INC. | $376.03 | 2019-2025 | Fanapt |
| Lundbeck LLC | $369.86 | 2019-2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $369.82 | 2020-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $343.55 | 2019-2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $280.60 | 2021-2023 | Lybalvi, Aristada |
| Abbvie INC. | $172.82 | 2021-2023 | |
| Allergan, INC. | $124.94 | 2019-2020 | |
| Eisai INC. | $56.67 | 2020-2022 | |
| Corium, LLC | $46.55 | 2023-2025 | Azstarys |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $45.42 | 2022 | |
| Shire North American Group INC | $36.44 | 2019 | |
| Almatica Pharma LLC | $35.48 | 2022-2023 | Loreev Xr |
| Bausch Health US, LLC | $33.81 | 2022 | |
| Validus Pharmaceuticals LLC | $20.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.